VERICEL CORPORATION Debt Conversion, Converted Instrument, Amount
VERICEL CORPORATION (VCEL) reported Debt Conversion, Converted Instrument, Amount of $0 for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2017-11-07
- VERICEL CORPORATION debt conversion, converted instrument, amount for the quarter ending 2016-12-31 was $0.00.
- VERICEL CORPORATION debt conversion, converted instrument, amount for fiscal 2016 was $190.00K.
- VERICEL CORPORATION debt conversion, converted instrument, amount for fiscal 2015 was $0.00.
- VERICEL CORPORATION debt conversion, converted instrument, amount for fiscal 2014 was $0.00.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|
| 2017-09-30 | $0.00 10-Q · filed 2017-11-07 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $190.00K 10-K · filed 2017-03-13 | |
| 2016-09-30 | $190.00K 10-Q · filed 2017-11-07 | ||
| 2015-12-31 | $0.00 10-K · filed 2017-03-13 | ||
| 2014-12-31 | $0.00 10-K · filed 2017-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |